PE20010402A1 - Derivados de 1,5-dihidropirrol-2-ona sustituida - Google Patents

Derivados de 1,5-dihidropirrol-2-ona sustituida

Info

Publication number
PE20010402A1
PE20010402A1 PE2000000761A PE0007612000A PE20010402A1 PE 20010402 A1 PE20010402 A1 PE 20010402A1 PE 2000000761 A PE2000000761 A PE 2000000761A PE 0007612000 A PE0007612000 A PE 0007612000A PE 20010402 A1 PE20010402 A1 PE 20010402A1
Authority
PE
Peru
Prior art keywords
alkyl
heteroaryl
aryl
cor8
dihydropyrrolt
Prior art date
Application number
PE2000000761A
Other languages
English (en)
Inventor
Michael Przewosny
Hans-Dietrich Stachel
Hermann Poschenrieder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20010402A1 publication Critical patent/PE20010402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,5-DIHIDROPIRROL-2-ONA DE FORMULA I, DONDE: X ES O, S, NR7; R1 ES H, OR11, SR11, COR8, CSR8, NR9R10, ALQUILO C1-C10, ARILO, HETEROARILO; R2 Y R3 SON H, F, Cl, Br, CF3, OR11, SR11, NR9R10, ALQUILO C1-C10, ARILO, HETEROARILO; R4 ES H, OH, OR11, SR11, COR8, COOR8, ALQUILO C1-C10, ARILO, HETEROARILO; R5 Y R6 SON H, O, OH, OR11, SR11, COR8, CSR8, COOR8, COCOR8, CONR9R10, CSNR9R10, ALQUILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS. R7 ES H, OR11, SR11, COR8, COOR8, COCOR8, ENTRE OTROS; R8 ES H, OR11, SR11, NR9R10, ALQUILO C1-C10, ENTRE OTROS; R9 ES ALQUILO C1-C10, HETEROARILO, ARILO, ALQUILENO C1-C6, ENTRE OTROS; R10 ES ALQUILO C1-C10, HETEROARILO, ARILO; R11 ES ALQUILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS ACIDO 1-METIL-3-ACETAMIDO-5-ETOXIMETILENTETRAMICO, ACIDO 3-ACETAMIDO-5-ETOXIMETILENTETRAMICO, 5-BENCILIDEN-4-METOXI-3-NITROSO-1,5-DIHIDROPIRROL-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I TIENEN AFINIDAD POR EL PUNTO DE LIGADURA DE GLICINA DEL CANAL RECEPTOR NMDA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DOLORES, REACCIONES INFLAMATORIAS, ALERGICAS, DEPRESIONES, ABUSO DE FARMACOS, ALCOHOL, GASTRITIS, DIARREA, INCONTINENCIA URINARIA, AFECCIONES CARDIOVASCULARES, ENFERMEDADES DE LAS VIAS RESPIRATORIAS, TOS
PE2000000761A 1999-08-06 2000-08-01 Derivados de 1,5-dihidropirrol-2-ona sustituida PE20010402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19936719A DE19936719A1 (de) 1999-08-06 1999-08-06 Substituierte 1,5-Dihydropyrrol-2-on-Derivate

Publications (1)

Publication Number Publication Date
PE20010402A1 true PE20010402A1 (es) 2001-05-05

Family

ID=7917172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000761A PE20010402A1 (es) 1999-08-06 2000-08-01 Derivados de 1,5-dihidropirrol-2-ona sustituida

Country Status (25)

Country Link
US (1) US6642267B2 (es)
EP (1) EP1200402B1 (es)
JP (1) JP2003506437A (es)
KR (1) KR20020025214A (es)
CN (1) CN1378532A (es)
AR (1) AR028848A1 (es)
AT (1) ATE304530T1 (es)
AU (1) AU782435B2 (es)
BR (1) BR0013311A (es)
CA (1) CA2381033A1 (es)
CO (1) CO5200758A1 (es)
CZ (1) CZ2002441A3 (es)
DE (2) DE19936719A1 (es)
ES (1) ES2248104T3 (es)
HK (1) HK1046405A1 (es)
HU (1) HUP0201937A3 (es)
IL (1) IL147977A0 (es)
MX (1) MXPA02001212A (es)
NO (1) NO20020574L (es)
NZ (1) NZ516988A (es)
PE (1) PE20010402A1 (es)
PL (1) PL353854A1 (es)
SK (1) SK1702002A3 (es)
WO (1) WO2001010833A1 (es)
ZA (1) ZA200201788B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP2792347A1 (en) 2005-09-28 2014-10-22 Auris Medical AG Pharmaceutical compositions for the treatment of inner ear disorders
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
DK2475428T3 (en) 2009-09-11 2015-09-28 Probiodrug Ag Heterocyclic derivatives as glutaminylcyklaseinhibitorer
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
UA114704C2 (uk) 2011-01-10 2017-07-25 Зінфандел Фармасьютікалз, Інк. Способи та лікарські засоби для лікування хвороби альцгеймера
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) * 2016-12-06 2020-07-07 Intelligrated Headquarters, Llc Phased deployment of scalable real time web applications for material handling system
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL258360A (es) * 1960-11-25
GB2173499A (en) * 1985-02-04 1986-10-15 Ici Plc Fungicidal dithiolopyrrolones
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
HUP0201937A2 (en) 2002-10-28
NZ516988A (en) 2004-11-26
ES2248104T3 (es) 2006-03-16
JP2003506437A (ja) 2003-02-18
CA2381033A1 (en) 2001-02-15
ATE304530T1 (de) 2005-09-15
NO20020574D0 (no) 2002-02-05
PL353854A1 (en) 2003-12-01
DE50011178D1 (de) 2005-10-20
HK1046405A1 (zh) 2003-01-10
CN1378532A (zh) 2002-11-06
AU6827900A (en) 2001-03-05
MXPA02001212A (es) 2002-07-02
EP1200402A1 (de) 2002-05-02
CZ2002441A3 (cs) 2002-05-15
AU782435B2 (en) 2005-07-28
AR028848A1 (es) 2003-05-28
US20020161033A1 (en) 2002-10-31
KR20020025214A (ko) 2002-04-03
IL147977A0 (en) 2002-09-12
BR0013311A (pt) 2003-01-28
NO20020574L (no) 2002-03-25
CO5200758A1 (es) 2002-09-27
DE19936719A1 (de) 2001-02-15
US6642267B2 (en) 2003-11-04
EP1200402B1 (de) 2005-09-14
HUP0201937A3 (en) 2002-12-28
ZA200201788B (en) 2003-08-27
SK1702002A3 (en) 2002-07-02
WO2001010833A1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
PE20010402A1 (es) Derivados de 1,5-dihidropirrol-2-ona sustituida
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
SE0104334D0 (sv) Therapeutic agents
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
HK57197A (en) Naphthalene derivatives procedure for their preparation and pharmaceutical compositions containing them
CO5271691A1 (es) Nuevos compuestos
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
DE60039359D1 (de) Amide als pyruvatdehydrogenaseinhibitoren
RU2007122406A (ru) Производные тетралина и индана и их применения в качестве антагонистов 5-нт
RU2007123251A (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
DE69229442T2 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
SE9903997D0 (sv) New compounds
RU2002110328A (ru) Препарат замещенных бензимидазолов
SE0201658D0 (sv) Immediate release pharmaceutical formulation
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
CA2425199A1 (en) Formulation of substituted benzimidazoles
KR910004568A (ko) 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
PT95990A (pt) Processo para a preparacao de novos derivados do tiofeno
RU2222541C2 (ru) Оптически активные производные пирролопиридазина, способы их получения, фармацевтическая композиция и агент на их основе, способ лечения или профилактики язвенной болезни
SE0104333D0 (sv) Therapeutic agents
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed